At a Glance
Aqualung Therapeutics Corporation is An early stage biotech company developing a therapeutic antibody to reduce inflammation in acute and chronic lung diseases. Aqualung Therapeutics Corporation has identified an upstream pathway and target which is a key contributor to the inflammatory storm associated with ventilator-induced lung injury as well as other chronic lung disorders such as pulmonary fibrosis, pulmonary arterial hypertension or radiation -induced lung injury.
The Problem
- Unchecked inflammatory cascades are a root cause of the excessive morbidity and mortality in acute and chronic inflammatory lung disorders
- The majority of ICU patients require mechanical ventilation (MV) for respiratory failure, however, MV directly causes lung inflammation and injury and contributes to ICU deaths, a syndrome known as Ventilator-Induced Lung Injury (VILI)
- Approximately 40% of (ICU) patients are placed on mechanical ventilation within 24 hours of ICU admission
About Aqualung
Therapeutics
At A Glance
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque eleifend eros eu enim tempor efficitur. Maecenas a enim sapien. Sed fringilla efficitur sem, id interdum risus vestibulum vitae.
Management
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque eleifend eros eu enim tempor efficitur. Maecenas a enim sapien. Sed fringilla efficitur sem, id interdum risus vestibulum vitae.
Clinical Advisory Board
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque eleifend eros eu enim tempor efficitur. Maecenas a enim sapien. Sed fringilla efficitur sem, id interdum risus vestibulum vitae.
JOE “SKIP” G.N. GARCIA
Md Founder And Chief
Executive Officer
EDDIE T. CHIANG
Ma,
Chief Operating Officer
SARA M. CAMP
Ba,
Chief Research Officer
STAN MIELE
Ba, Chief Business
trategy Officer
THE PROBLEM
Increased lung inflammation is a key contributor to increased mortality in acute and chronic lung disease. There are NO current therapies that effectively prevent or reduce lung inflammatory burden.
